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Reversal by RARa agonist Am580 of c-Mycinduced imbalance in RARa/RARg expression
during MMTV-Myc tumorigenesis
Almudena Bosch1, Silvina P Bertran1, Yongke Lu1, Avalon Garcia1, Alexis M Jones1, Marcia I Dawson2 and
Eduardo F Farias1*

Abstract
Introduction: Retinoic acid signaling plays key roles in embryonic development and in maintaining the
differentiated status of adult tissues. Recently, the nuclear retinoic acid receptor (RAR) isotypes a, b and g were
found to play specific functions in the expansion and differentiation of the stem compartments of various tissues.
For instance, RARg appears to be involved in stem cell compartment expansion, while RARa and RARb are
implicated in the subsequent cell differentiation. We found that over-expressing c-Myc in normal mouse mammary
epithelium and in a c-Myc-driven transgenic model of mammary cancer, disrupts the balance between RARg and
RARa/b in favor of RARg.
Methods: The effects of c-Myc on RAR isotype expression were evaluated in normal mouse mammary epithelium,
mammary tumor cells obtained from the MMTV-Myc transgenic mouse model as well as human normal
immortalized breast epithelial and breast cancer cell lines. The in vivo effect of the RARa-selective agonist 4[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido]benzoic acid (Am580) was examined in the MMTVMyc mouse model of mammary tumorigenesis.
Results: Modulation of the RARa/b to RARg expression in mammary glands of normal mice, oncomice, and human
mammary cell lines through the alteration of RAR-target gene expression affected cell proliferation, survival and
tumor growth. Treatment of MMTV-Myc mice with the RARa-selective agonist Am580 led to significant inhibition
of mammary tumor growth (~90%, P<0.001), lung metastasis (P<0.01) and extended tumor latency in 63% of mice.
Immunocytochemical analysis showed that in these mice, RARa responsive genes such as Cyp26A1, E-cadherin,
cellular retinol-binding protein 1 (CRBP1) and p27, were up-regulated. In contrast, the mammary gland tumors of
mice that responded poorly to Am580 treatment (37%) expressed significantly higher levels of RARg. In vitro
experiments indicated that the rise in RARg was functionally linked to promotion of tumor growth and inhibition
of differentiation. Thus, activation of the RARa pathway is linked to tumor growth inhibition, differentiation and cell
death.
Conclusions: The functional consequence of the interplay between c-Myc oncogene expression and the RARg to
RARa/b balance suggests that prevalence of RARg over-RARa/b expression levels in breast cancer accompanied by
c-Myc amplification or over-expression in breast cancer should be predictive of response to treatment with RARaisotype-specific agonists and warrant monitoring during clinical trials.
See related editorial by Garattini et al http://breast-cancer-research.com/content/14/5/111
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Introduction
The retinoic acid (RA) nuclear receptor isotypes retinoic
acid receptor (RAR)a, RARb and RARg have many overlapping as well as unique functions [1-4]. The RARs
belong to the steroid/thyroid hormone superfamily of
ligand-dependent transcription factors [5-8], bind both
all-trans retinoic acid (ATRA) and its isomer, 9-cis RA,
and form heterodimers with the retinoid × receptor isotypes (RXRs a-g) [9]. ATRA functions as a pan-agonist of
all three RAR isotypes thereby playing crucial roles in
embryonic morphogenesis, cell differentiation and maintenance of adult epithelia [10,11]. These findings together
with preclinical, epidemiological and clinical observations
[12] have prompted extensive inquiries into ATRA’s
potential use as an anti-tumor agent. Despite its demonstrated anti-tumor activity in vitro and in a limited number of cancer models [13-21] and the highly positive
response observed in acute promyelocytic leukemia
patients [22-24], clinical trials using ATRA as a treatment
for solid tumors have produced disappointing results
overall [25-29].
Although the RAR isotypes display overlapping functions as evidenced by their ability to modulate common
target genes [30,31], Husman et al. [32] described evidence of antagonism between RAR isotypes. Specifically,
RARg1 inhibited functions of other RAR isotypes. In
addition, different RAR isotypes can transcribe the same
target gene with different efficiencies, with transcription
further modulated by their phosphorylation status. Moreover, interactions between isotypes are dynamic and
affected by both intracellular and extracellular environments such as changes in cell signaling induced by oncogenic stress and global kinase activity [33].
Studies of the RAR isotypes and their roles in mammary development and breast cancer provide the first
clues to the unique activities that certain RAR isotypes
have and suggest that certain isotype-selective retinoids
may have therapeutic potential against breast cancer. It
was shown that specific activation of RARa induces the
expression of RARb, which is required for normal tissue
differentiation [10,11]. Similarly, activation of RARa also
induced the expression of the cellular retinol-binding
protein-1 (CRBP1), a key retinol chaperone in the cellular
metabolism of retinol to ATRA, and maintained the differentiated status of the mature epithelial phenotype
[34-37]. In contrast, the RARg isotype had pro-tumorigenic activity in liver cancer models [38], and its activation stimulated breast cancer cell proliferation [39]. On
this basis, we tested whether the unique functions of
these RAR isotypes could be translated into an effective
approach to anti-tumor therapy. To achieve this goal we
selected the synthetic retinoid Am580, which is reported
to be an RARa-selective transcriptional agonist [40] that
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does not activate RARg [40]. Previously, we showed that
in the MMTV-Wnt1 and MMTV-Neu transgenic mouse
models of breast cancer, in which the oncogene expression is driven by the mouse mammary tumor virus promoter (MMTV), treatment with Am580 [40] significantly
prolonged tumor-free survival and impaired tumor
growth [39]. In contrast, treatment of MMTV-Neu transgenic mice with the RAR isotype pan-agonist ATRA,
which also activates RARg, promoted tumor growth [41].
Most importantly, these results further demonstrated the
reciprocal relationship between RARa and RARg,
whereby direct inhibition of RARg activity either by a
specific RARg antagonist or by indirect inhibition by
ligand-mediated RARa activation leading to down-regulation of RARg, allowed expression of RARa and its target genes, RARb and CRBP1. Blocking RARg while
simultaneously activating RARa, strongly impinged on
oncogene-induced growth pathways to attenuate the
transforming potential of both Neu and Wnt1 oncogenes
[39,42,43].
This newly discovered cross-regulation of RAR isotypes, coupled with the cancer-promoting role of RARg
and anti-cancer role of RARa, prompted us to investigate
their roles in the MMTV-Myc mammary cancer mouse
model, in which parous females develop mammary carcinomas with 100% incidence following a latency period of
several months. This model is representative of about
30% of human breast cancer cases in which c-Myc is
amplified and/or over-expressed [44]. The c-myc gene is
often over-expressed in tumors having mutations in the
BRCA1 gene [44]. By forming a heterodimer with Max,
c-Myc transactivates several proliferation-related genes
and consequently prevents Max from forming a Mad/
Max heterodimer [45,46] that represses transcription of
cell-cycle/growth arrest genes such as p21 waf1/CIP1 ,
p27 kip1 and gadd45, and the angiogenesis inhibitor
thrombospondin-1 [47-49], which are also RARa regulated genes.
Here, we examined whether c-Myc over-expression
affected the expression of RAR isotypes and their target
genes in normal mouse mammary gland epithelial cells.
The goal was to determine whether RARg expression was
enhanced and whether this increase affected c-Mycinduced tumor growth. We also evaluated whether specific
activation of RARa by Am580 had anti-tumor effects in
c-Myc-induced tumorigenesis.
Overall, our results bring new insights to our understanding of the effect of the c-Myc oncogene on RAR
isotype expression, c-Myc/RAR isotype reciprocal relationships, and the novel tumor-promoting role of RARg.
We propose that the characterization of RAR expression
in breast cancer will identify patients that would benefit
from RAR isotype-selective retinoid treatment.
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Materials and methods
Antibodies

Antibody sources were as follows: anti-p27 and anti-Ecadherin (BD Transduction Labs, Hoboken, NJ, USA);
anti-CYP26A1 and anti-CRBP1 (Santa Cruz Biotechnology, CA); anti-RARa, -RARb and -RARg (Abcam, Cambridge, MA, USA), anti-Akt, anti-pAkt anti-pErk, anti-Erk
and anti-pRB (Cell Signaling, Beverly, MA, USA); antiGAPDH (Calbiochem, Gibbstown, NJ, USA); anti-tubulin
(Sigma Diagnostics, St. Louis, MO, USA).
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pad of the inguinal mammary glands (gland numbers 4
and 8) under soft anesthesia and analgesia in accordance
with the Institutional Animal Care and Use Committee
(IACUC) guidelines.
In Vivo protocol approval

Protocols designed and used in the in vivo experiments
were approved by the Mount Sinai School of Medicine
(MSSM) IACUC and conducted following its guidelines.
Immunohistochemistry

Immunoblotting

Tumor samples were mechanically homogenized in radioimmunoprecipitation assay (RIPA) buffer (1% Triton X100, 10 mM Tris, pH 8, 140 mM NaCl, and 0.1% SDS).
Primary cultures derived from wild type FVB mice mammary gland epithelium were washed in PBS, pH 7.4, and
lysed with RIPA buffer. Immunoblotting was performed
following standard procedures as described previously
[39].

Tumor samples were fixed in 10% buffered formalin for 24
h, transferred to 70% ethanol and kept at 4ºC until use.
Sections were prepared from eight tumors per group, subjected to standard antigen retrieval and incubated with primary antibody overnight at 4ºC. Sections were processed
using the VectaStain ABC Elite Kit (Vector Laboratories,
Burlingame, CA, USA), signals were detected using the
Metal Enhanced DAB Substrate Kit (Pierce Laboratories,
Rockford, IL, USA) and sections counterstained with
Harris Hematoxylin Solution (Sigma Diagnostics).

In vivo studies

Three-month-old uniparous MMTV-Myc female mice
(NCI Frederick Mouse Repository, Frederick, MD, USA)
(30 mice/group) were fed with 0.3 mg/kg/day of the RARa
agonist Am580 (4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl2-naphthyl)carboxamido]benzoic acid), which was kindly
provided by Dr K Shudo (Research Foundation Itsuu
Laboratory, Tokyo, Japan). Am580 was mixed into their
regular diet by the vendor (Purina 5053, Richmond, IN,
USA). Food consumption was measured to calculate the
amount of Am580 to be added to the diet to achieve the
daily dose as described previously [39]. Regular diet was
used as the control. Because the objective was to study the
effect of Am580 on tumor initiation and development,
mice that developed tumors within the first month were
removed from the study on the assumption that their
tumors had developed before treatment began. Mice were
palpated twice weekly and the onset of tumor development was recorded. Once palpable, the tumor sizes were
measured weekly in two dimensions and volumes calculated using the equation Vol = Dxd2/2 (where D = major
diameter and d = minor diameter). Tumor-free survival
was calculated from Kaplan-Meier curves, and statistical
significance was determined using the log-rank test for
survival and the t-test for tumor growth. Metastasis dissemination was evaluated by dissecting the lungs from
euthanized mice and inspecting the Bouin-fixed (Sigma,
St. Louis, MO, USA) lung surface for lesions using a
stereoscope (Nikon SMZ800 stereoscope X3 to X5). For
xenograft experiments, 8-week-old syngenic FVB mice
were used (NCI Frederick Mouse Repository). Cells or
tumor fragments were inoculated into the mammary fat

Cell lines, culture conditions and plasmid transfection

After euthanasia by CO 2 overdose, tumors from
untreated female MMTV-Myc mice and mammary
glands from wild-type-FVB female mice were removed by
dissection and minced into fragments, which were then
digested with 5 ml of 1.5 mg/ml collagenase (Sigma, St.
Louis, MO, USA) in PBS containing 25 mg/ml BSA
(Sigma), 100 mM Ca2+ and 100 mM Mg2+ per approximate 500 mg of tissue at 37ºC for 30 to 45 minutes with
gentle agitation. Cells were maintained in DMEM-F12
(Cellgro, Manassas, VA, USA) containing 5% (MMTVMyc cells) or 10% (wt-FVB cells) fetal bovine serum
(FBS) and 4 μg/ml insulin (Sigma Diagnostics). Immortalized nontumorigenic human MCF-10A breast epithelial
cells, which were a generous gift from Dr J Brugge
(Department of Cell Biology, Harvard Medical School,
Boston, MA, USA), were maintained as described by
Debnath et al. [50]. Human breast cancer MCF-7 (ER+)
and MDA-MB-231 (ER -) cells were obtained from the
American Tissue Culture Collection (ATCC, Manassas,
VA, USA). Both cell lines were propagated using ATCC
protocols. FVB or Myc cells were transfected with either
pSG5-empty, pSG5-RARg, pSG5-mCRBP1 (kindly provided by Dr Chambon, IGBMC, Strasbourg, France),
pcDNA3, or pcDNA3-h-c-Myc (Addgene, Ricci et al.
[51]) vectors using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) in Opti-MEM (Gibco, Carlsbad, CA,
USA). At 24 h after transfection, cells were treated for 16
h with 1 μM ATRA (Sigma, St. Louis, MO, USA) in
dimethyl sulfoxide (DMSO) (0.01% final concentration;
Sigma Diagnostics).
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siRNA transfection using Lipofectamine RNAiMAX

MCF-10A, MCF-7 and MDA-MB-231 cells were plated
and grown to 30 to 40% confluence at 24 h. One hour
prior to transfection the medium was replaced with 1X
Opti-MEM reduced serum medium (Gibco, Carlsbad, CA,
USA). Anti-RARg siRNA and a scramble control siRNA
sequence (Sigma-Aldrich; seq1 #SASI_Hs01_00012455,
seq2 #SASI_Hs01_00012456, Scramble seq #SIC001) were
transfected according to the Invitrogen protocol using
Lipofectamine RNAiMax reagent (Invitrogen catalogue
number 13778-075, Grand Island, NY, USA).
Cell lines and 3D cultures

Primary Myc cell suspensions obtained after a 45-minute collagenase digestion (1.5 mg/ml collagenase and
25 mg/ml BSA in PBS plus 100 mM Ca2+ and 100 mM
Mg2+) of MMTV-Myc tumor fragments were grown in
DMEM/F12 medium supplemented with 5% horse
serum, 100 ng/ml cholera toxin, 5 mg/ml insulin,
0.5 mg/ml hydrocortisone, 1% Pen/Strep, 1% glutamine
(Gibco), 1% non-essential amino acids (Invitrogen) and
20 ng/ml EGF (PeproTech, Rock Hill, NJ, USA). Cells
were transfected with shRARg(2 μg) in 35-mm dishes,
following the manufacturer’s instructions (Open Biosystems, Huntsville, AL, USA) and seeded (3 × 103/well) in
quadruplicate onto Matrigel® (BD Bioscience, San Jose,
CA, USA) beds in 8-well culture slides (BD Bioscience,
Bedford, MA, USA) to prepare three-dimensional cultures as described by Debnath et al. [50]. The media was
changed every 48 h for 8 consecutive days. An additional
shRARg transfection was done at day 4 to maintain RARg
knockdown. Colony morphology was determined by
phase-contrast microscopy. RARs were silenced using
shRNAs from Open Biosystems (Open Biosystems,
Huntsville, AL, USA) shRARa (Oligo ID: V2MM_6881) ,
shRARb (Oligo ID: V2HS_239292) or shRARg (Oligo ID:
V2MM_62330). Scrambled shRNA (Open Biosystems,
Huntsville, AL, USA) was used as the control.
Proliferation assay

Primary Myc cells (2 × 104) were seeded in triplicate in 6well culture dishes and allowed to attach overnight. They
were then washed with culture medium and treated with
the RARg antagonist SR11253 (2-(4-carboxyphenyl)-2(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1,3dithiolane) at increasing doses (10, 50 and 250 nM) or with
DMSO (0.001% final concentration) alone, and then
detached with 0.05% trypsin (Gibco) and counted every
24 h for 4 days. Statistical significance was determined by
t-test. Following the same protocol described above for
Myc, MCF-10A, MCF-7 and MDA-MB-231 cells were
treated with 1 μM ATRA (RAR pan-agonist), 200 nM
Am580 (RARa agonist), 100 nM CD437 (the RARg/b

Page 4 of 19

agonist 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid, AHPN) (Sigma), 30 nM BMS961 (the
RARg agonist 3-fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino]
benzoic acid) (Tocris, Bristol, UK) and SR11253 or DMSO
(0.001% final concentration) alone as the control.
Real-time PCR

Total RNA from FVB mammary gland epithelial cells was
isolated using the RNeasy mini kit (Qiagen, Valencia, CA,
USA) and reverse-transcribed using the iScript cDNA
synthesis kit (Bio-Rad, Philadelphia, PA, USA). cDNA was
amplified by real-time PCR using an iQ5 Real-Time PCR
detection systems kit (Bio-Rad) and SYBR green PCR master mix (Applied Biosystems, Carlsbad, CA, USA). Primer
sequences were: RARg1-sense: 5’-TGG GGC CTG GAT
CTG GTT AC-3’, RARg1-antisense: 5’-TTC ACA GGA
GCT GAC CCC AT; RARg2-sense: 5’-GCC GGG TCG
CGA TGT ACG AC and RARg2-antisense: 5’- TTC ACA
GGA GCT GAC CC CAT; RARb2-sense: 5’-ATG GAG
TTC GTG GAC TTT TCT GTG-3’ and RARb2-antisense:
5’-CTC GCA GGC ACT GAC GCC AT-3’; CRBP1-sense:
5’-ACG GGT ACT GGA AGA TGC TG-3’ and CRBP1antisense: 5’-CCA TCC TGC ACG ATC TCT TT-3’;
Hmq-c-Myc-sense: 5’-AGC GAC TCT GAG GAG GAA
CA-3’ and Hmq-c-Myc-antisense: 5’-AGT GGG CTG
TGA GGA GGT TT-3’; GAPDH-sense: 5’-CGT AGA
CAA AAT GGT GAA GG-3’ and GAPDH-antisense: 5’GAC TCC ACG ACA TAC TCA GC-3’.
Chromatin immunoprecipitation assay

Cells from FVB mammary gland epithelium were isolated
as described above and seeded in 140-mm plates precoated with Matrigel ® (BD Bioscience, San Jose, CA,
USA). At 70% confluency, cells were transfected with
pSG5 or pSG5-RARg (10 μg) using Lipofectamine 2000 in
Opti-MEM, 24 h after transfection, cells were treated with
1 μM ATRA for 16 h, and then crosslinked using 1% formaldehyde. Cell nuclei were isolated using hypertonic buffer A (150 mM NaCl, 50 mM Tris-HCl, pH 8, 1% NP40,
1% sodium deoxycholate, 0.5% SDS, and 2 mM EDTA),
centrifuged, lysed in SDS lysis buffer (50 mM Tris, pH
8,10 mM EDTA, 1% SDS), and then sonicated. Chromatin
from the nuclear fraction obtained was pre-cleared with
protein G agarose/sperm salmon (Millipore, Billerica, MA,
USA) and irrelevant immunoglobulin G (IgG). RARg was
immunoprecipitated overnight at 4°C, and immunoprecipitates were incubated with protein G agarose/sperm salmon for 2 h at 4°C. Immunoprecipitates were washed and
eluted with elution buffer (100 mM Na2CO3 and 1% SDS)
from agarose beads and incubated in 5 M NaCl at 65°C
overnight. DNA was isolated by digestion with proteinase
K, treatment with RNAse A, and purification using the
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QIAquick DNA purification kit (Qiagen, Valencia, CA,
USA). Primers for the detection of the RA response element (RARE) sequence of CRBP1 were designed based on
Smith et al. [52]: CRBP1-sense 5’-CTT GCC TAC CCT
GAT GGT GT-3’ and CRBP1-antisense: 5’-CCC TTC
TCA CCT GCT ACC TG-3’. As a control, nonspecific primers were designed using 9000-bp upstream of the CRBP1
promoter; nonspecific-sense: 5’-GCA AGA CTG CTT
GCT CTC CT-3’ and nonspecific-antisense: 5’-AAC ACA
TCG TGG GTG GTC TT-3’.

Results
c-Myc up-regulates RARg expression leading to downregulation of RARa target gene, CRBP1

We hypothesized that over-expression of c-Myc in the
mammary epithelium of MMTV-Myc transgenic mice
leads to up-regulation of RARg and determine if this upregulation happens before the development of palpable
tumors. To test this hypothesis, we compared RARg
expression in mammary gland epithelium isolated from
15-week-old virgin MMTV-Myc female mice, at which
point the mammary epithelium is already hyperplastic, to
that of primary mammary epithelium from wt-FVB female
mice of the same age. Quantitative (Q)-PCR results
(Figure 1A) revealed that compared to normal epithelium,
the MMTV-Myc mouse hyperplastic epithelium had elevated levels of RARg1 and g2 mRNA and reduced RARb2,
which is commonly silenced in cancer [53]. Western blot
analysis confirmed that compared to primary cells cultured from normal FVB mammary epithelium, Myc
tumors had elevated RARg but reduced RARb protein
levels, whereas RARa levels remained unchanged (Figure
1B). Moreover, the elevation in the level of RARg protein
in c-Myc over-expressing cells compared to that in normal
FVB cells, appeared to correlate with the reduction in the
level of CRBP1 protein (Figure 1C).
To determine whether modulation of RARg and CRBP1
were functionally linked to c-Myc expression, primary
cultures of FVB mammary epithelial cells were transfected with c-Myc or a control vector (c-Myc expression
is shown in Figure S1A in Additional file 1) and for the
transfected cells were evaluated for the expression of
RARg and that of the RARa target genes CRBP1 and
RARb [5-8]. Forced expression of c-Myc specifically elevates RARg1 mRNA relative to the vector control, but
not that of RARg2 (Figure 1D). Knockdown of RARg1 in
primary Myc cells using shRARg1 (Figure S1B in Additional file 1) followed by Am580 treatment resulted in an
even higher level of CRBP1 expression (Figure 1E), showing that in these cells RARg has a repressive effect on the
RARa target gene CRBP1.
These results suggest that when the RARg ligand is
absent or present only at low physiologic concentration,
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RARg over-expression represses CRBP1 expression, but
this effect is independent of its canonical activation.
RARg has a pro-tumorigenic function in c-Myc-induced
tumorigenesis

Our results suggest that RARg is involved in the repression of RARb and CRBP1 expression, both of which
have a tumor-suppressive function [54]. To determine
whether RARg has a pro-tumorigenic function in the
context of c-Myc-driven transformation, RARg was
either stably knocked down or over-expressed in primary Myc cells and inoculated orthotopically into the
mammary fat pad of syngeneic FVB mice. After 20 days,
the tumors formed by RARg null myc cells displayed a
60% reduction in size in comparison to those formed by
Myc-control cells. The Myc cells in which RARg was
over-expressed produced approximately 40% larger
tumors (Figure 2A and 2B). These results allude to the
fact that RARg is likely to confer pro-tumorigenic
activity.
Immunohistological analysis of tumor sections isolated
from mice implanted with shRARg-transfected Myc cells
showed increased expression of p27 (Figure 2C), which
is a marker of cell-cycle arrest [55], and membraneassociated E-cadherin (Figure 2D arrow), which is a
marker of epithelial cell differentiation [56].
Given the pro-tumorigenic activity of RARg, we examined the effect of RARg knockdown on tumor invasiveness by generating three-dimensional cultures. In this
approach, Myc cells were oligofected with siRARg both
before being plated in Matrigel® as described by Debnath
et al. [50] and then again on day 4. The colonies were
then cultured for 8 days before the size and morphology
of the resulting colonies were determined. Colonies
formed by control cells transfected by vector alone were
large (>200 um) and invasive, with long matrix-penetrating spikes. In contrast, the siRARg-transfected cells developed only small (around 100 μm), smooth, rounded
acinar-like colonies. The difference in invasiveness
between control and siRARg-transfected cells was quantified by counting 100 colonies per group (n = 4 wells/
group) and was found to be highly statistically significant
(Figure 2E).
In addition to knocking down RARg, we also
explored the effect of pharmacologic inhibition of its
activity using the RARg antagonist SR11253 [57,58] in
Myc cells in vitro. SR11253 treatment reduced Myc
cell proliferation in a dose-dependent manner (IC 50
value = 50 nM after 96 h) (Figure 2F). The anti-proliferative effect achieved by reducing the expression of
RARg coincided with up-regulation of p27 and downregulation of pRb, as shown by confocal immunofluorescence (Figure 2G).
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Figure 1 Retinoic acid receptor (RAR)g cooperates in Myc-induced tumorigenesis and down-regulation of RARb2 and CRBP1.
A) Quantitative (Q)-PCR analysis of RARg1, g2 and b2 expression in normal (FVB mammary epithelial cells, MEC) and hyperplastic (Myc MEC)
mammary epithelium. B) Western blot analysis of the RAR isotypes in FVB mammary gland epithelium and MMTV-Myc tumors (three primary
cultures/experimental group). C) Western blot analysis of RARg and CRBP1 in Myc tumors and in normal FVB mammary epithelium. D) Q-PCR
analysis of RARb2, RARg1, RARg2 and CRBP1 expression in FVB cells transfected with a vector control or c-Myc. E) Induction of CRBP1 protein by
Am580. Primary cultured Myc MECs or those stably transfected with shRARg (Figure S1 in Additional file 1) were treated with 200 nM Am580 for
48 h. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein was used as a loading control.

These results show that c-Myc over-expression
increases the level of RARg. Up-regulation of RARg led
to proliferation and invasiveness.
RARg supports proliferation and survival of human breast
cell lines

In order to determine if the pro-proliferative effect of
RARg in the Myc-expressing mouse mammary tumor cells
is also present in human mammary cells, RARg was

knocked-down with siRNAs in immortalized non-tumorigenic human MCF-10A cells, estrogen receptor (ER+ )
MCF-7 cells and triple negative (ER-/progesterone receptor-/HER2-) MDA-MB-231 breast cancer cells. As shown
in Figure 3A-C, the proliferation of all three cell lines was
significantly impaired by RARg knockdown. Treatment
with 200 nM Am580 enhanced the anti-proliferative effect
exhibited by RARg knockdown in the MCF-10A and MCF7 cell lines but not in the MDA-MB-231 cells. The lack of
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Figure 2 Retinoic acid receptor (RAR)g modulates tumor cell growth, differentiation and morphology in MMTV-Myc xenografts in FVB
mice. A) Primary cells from MMTV-Myc tumors were isolated and cultured. They were then transfected with the control vector pSG5 or a vector
tethered to shRARg or pSG5-RARg, shRARg or pSG5-RARg plasmids. Transfected cells (0.5 × 106) were inoculated orthotopically into the abdominal
mammary gland fat pad (gland number 4) of 10 FVB female mice, whereas their contralateral fat pad was inoculated with pSG5-transfected cells
to serve as an internal control. Tumor volume shown is after 15 days of in vivo growth. Results shown are representative of two independent
experiments. B) Immunoblotting of tumor cell lysates with anti-RARg antibody showing the levels of RARg in the shRARg and pSG5-RARgtransfected Myc cells. Immunohistochemical analysis of five sections per group of tumors derived from the shRARg-transfected cells compared to
the vector control cells (C and D). C) Expression of cell growth-arrest marker p27 (brown); space bar = 100 um. D) Expression of differentiation
marker E-cadherin. Plasma membrane-associated E-cadherin was detected in the shRARg tumors (open arrow); space bar = 20 um.
E) Morphologic analysis of Myc cells cultured under three-dimensional conditions in Matrigel® (4 wells/group); bar = 100 μm. The number of
colonies exhibiting the invasive (t-test P < 0.0001, light-gray bars) and noninvasive (t-test P < 0.0001, dark-gray bars) phenotype was quantified.
F) RARg antagonist SR11253 inhibits Myc tumor cell proliferation in a dose-dependent manner. Proliferating Myc cells were treated with
increasing concentrations of SR11253 as shown. G) Confocal immunofluorescence for p27 (cell arrest marker, red) and pRB (proliferation marker,
green) in Myc cells transfected with the shRARg construct and in vector alone-transfected control cells; bar = 50 μm. Panels E, F and G are
representative of three independent experiments.
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Figure 3 Cell proliferation assays of human cell lines. A-C). Effect of knockdown of retinoic acid receptor (RAR)g on proliferation of human
MCF-10A immortalized, non-tumorigenic mammary epithelial cells (A), MCF-7 breast cancer cells (B) and MDA-MB-231 breast cancer cells
(C) using siRARg. Cells transfected with scrambled siRNA were used as controls. Treatment of siRARg-transfected cells with 4-[(5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphthyl)carboxamido]benzoic acid (Am580) (100 nM) in DMSO (0.01% final concentration) further reduced proliferation of
MCF-10A and MCF-7 cells, which express RARa, but did not reduce that of the RARa-negative MDA-MB-231 cells. D) Relative to c-Myc
expression in MCF-10A cells, that in MCF-7 and MDA-MB-231 cells was 38- and 55-fold higher, respectively, according to quantitative PCR. Results
shown are representative of two independent experiments.

an effect in MDA-MB-231 is most likely due to the low
expression level of RARa in these cells [59]. Although, cMyc expression was low in MCF-10A cells and high in
MCF-7 and MDA-MB-231 cells) (Figure 3D), this

difference did not impinge on the changes in the rate of
proliferation induced by modulation of RARg expression.
We treated the three human cell lines and Mycexpressing mouse mammary cells with RARg agonist
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BMS961, RARg/b agonist CD347 and RARg antagonist
SR11253 alone, or in combination with ATRA or
Am580. Similarly to the results obtained using RARg
knockdown (Figure 3), co-treatment of these cell lines,
including the mouse Myc cells, with the RARg antagonist SR11253 and RARa agonist Am580, resulted in
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strong growth inhibition (Figure 4). As expected,
Am580-inhibited MCF-10A- and MCF-7-cell growth
(Figure 4, upper panels) were growth-inhibited by
Am580, whereas RARg agonist BMS961 increased their
proliferation. Antagonist SR11253 inhibited the proliferation of MDA-MB-231 cells (Figure 4, lower left

Figure 4 Effect of retinoids on cell proliferation. Human MCF-10A, MCF-7, MDA-MB-231 and mouse Myc cells were treated for 96 h with
0.01% DMSO as control, 1 uM All-trans retinoic acid (ATRA) (retinoic acid receptor, RAR, pan-agonist), 200 nM Am580 (RARa agonist), 100 nM
CD437 (RARg and b agonist), 30 nM BMS961 (RARg agonist), 200 nM SR11253 (RARg antagonist), and combinations of 4-[(5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphthyl)carboxamido]benzoic acid (Am580) with CD437, BMS961 and SR11235 at the same concentrations. Cells were
counted at the end of the experiment. Results shown are representative of two independent experiments and confirmed by MTS (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) cell viability assays (not shown).
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panel), which was not further inhibited by combination
with Am580, as was expected due to their low expression of RARa. The general pattern of responses of the
Myc mouse cells to treatment was similar to the human
cells, except that the CD437/AHPN (RARg/b agonist)
and its combination with Am580 impaired cell proliferation most effectively (Figure 4, lower right panel). These
results show that the pro-proliferative effect of RARg is
ligand-dependent and more importantly, that it can be
targeted by RARg-specific antagonists such as SR11253,
alone or in combination with Am580.
To further examine the specific roles of the RAR isotypes, each one (a, b or g) was individually knocked down
in MCF-10A cells using specific shRNAs (Figure 5C).
Down-regulation of RARa or RARb altered the cellular
morphology from a more cobblestone-like structure to
that of a more spindle-like shape (Figure 5A), suggesting
that both isotypes could participate in control of epithelial to mesenchymal transition (EMT). In contrast,
down-regulation of RARg impaired cell survival, with
cells showing a progressively increasing unhealthy starlike morphology (Figure 5A, right panel). Confocal
immunofluorescence analysis using pRb (green) as a surrogate marker for proliferation and p27 (red) for cellcycle arrest, indicated that knocking down RARa or
RARb increased proliferation (increased pRb expression),
whereas knocking down RARg promoted cell-cycle arrest
(increased p27 expression). The p27 levels increased
further when shRARg-transfected cells were treated with
1 uM ATRA for 48 h (Figure 5B), suggesting that changing the ratio of RARa or b to RARg affects the cellular
response to ATRA.

Am580 responders). Analysis of the tumor growth rates
after initial tumor detection revealed two distinct subpopulations in the Am580-treatment group, those with
fast-growing tumors (Figure 6B, Am580 non-responders
denoted by squares) and those with slow-growing tumors
(Figure 6B, Am580-responders denoted by triangles). Of
27 treated mice available for evaluation at week 50, 17
(63%) responded to Am580 treatment with 90% reduction in tumor size relative to the untreated controls,
while 10 (37%) did not show a tumor size reduction
(non-responders) (Figure 6B). Comparison of the Am580
responders to the Myc-Ctrl group by Kaplan-Meier analysis showed that tumor latency in the responders was
significantly extended (P = 0.0465, log-rank test, Am580
R vs. Myc-Ctrl), with 35% of the treated Am580-responding mice not developing tumors at 50 weeks (Figure 6B).
Metastatic dissemination of tumor cells is the ultimate
cause of death in breast cancer with the lungs being one
of the major target organs for metastasis to occur [61].
Analysis of lung metastasis incidence and number of
metastatic lesions per mouse revealed that, compared to
untreated mice (Myc-Ctrl) of which 66.6% developed lung
metastases, only 16.6% of the Am580-responsive mice had
metastases. The incidence of metastases in Am580 nonresponsive mice was 71.4%, whereas compared to this
group, Am580 responders had 36.8% metastasis incidence.
The number of metastases per responder mouse was also
reduced by Am580 (Figure 6C). Together these results
demonstrate the ability of Am580 to reduce tumor growth
and aggressiveness in the MMTV-Myc tumor model.

Effects of RARa activation by Am580 on tumor latency,
growth and lung metastasis

Because the MMTV-Myc mouse is an inbred population,
we did not expect the difference in response to Am580 to
be host-dependent. However, to rule it out formally, two
tumors from each Am580 treatment group were excised,
minced and then inoculated into the mammary fat pads of
separate groups of syngenic FVB females, which have the
same genetic background of the MMTV-Myc transgenic
model. Inoculated mice were fed the diet containing
Am580 for 20 days. The transplanted tumors recapitulated
the individual patterns of response and non-response of
the original tumor (Additional file 2, Figure S2) indicating
that the response to Am580 was independent of the host
and intrinsic to the tumor.
We, therefore, tested whether an imbalance in RAR isotype expression defined the response to Am580 treatment.
Analysis of RAR isotype protein levels showed that
Am580 NR tumors expressed higher RARg protein levels
than Am580 R tumors (Figure 7A). To confirm that high
expression of RARg correlated with lack of responsiveness
to Am580, sections from untreated (control) and treated
responsive and nonresponsive tumors were examined for

Based on our prior work [39] and the above results, we
reasoned that use of a RARa-selective agonist might circumvent the pro-proliferative and pRb repressive effects
induced by activation of RARg [11] and thereby prevent
tumor development. To accomplish this goal, we selected
the RARa agonist Am580 [60], which was reported to
have 10-fold higher binding affinity for RARa than RARb
and no detectable affinity for RARg [40]. Uniparous,
15-week-old MMTV-Myc female mice, 30 per group,
were fed standard diet containing Am580 or the standard
diet alone (Myc-Ctrl group) and palpated twice weekly
for the appearance of tumors. Tumors were first noted at
week 16 in both experimental groups (control diet and
Am580 diet). At week 50, no significant difference in
tumor development was observed between the two
groups analyzed by Kaplan-Meier plot. At that time, 80%
of the Am580-treated mice and 100% of the control mice
had tumors (Figure 6A, Myc-Ctrl vs. Am580-treated; NR
+R, where NR are Am580 non-responders, and R are

Difference in Am580 response is related to the
RARa/RARg balance in tumors
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Figure 5 Down-regulation of retinoic acid receptor (RAR) isotypes in immortalized normal human mammary MCF-10A cells using
shRNA affects morphology and response to All-trans retinoic acid (ATRA). A) Phase-contrast micrographs of MCF-10A cells transfected with
shRNA against RARa, RARb or RARg show distinct effects on cell morphology compared to nontransfected control cells. Equal numbers of
transfected and control cells were seeded and then photographed after 48 h; bar = 20 μm. B) Confocal micrographs showing effects on MCF10A cell proliferation as determined by staining for cell-cycle arrest marker p27 (red) and proliferation marker pRB (green) after transfection with
shRARa, shRARb, shRARg or scrambled control (SCR) in the presence or absence of 1 uM ATRA; bar = 100 μm. C) Immunoblotting with isotypeselective antibodies illustrates silencing achieved with individual shRNAs. Tubulin was used as the loading control. Results shown are
representative of three independent experiments.
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Figure 6 Effect of Am580 treatment on mammary tumor development, tumor growth and metastatic dissemination in MMTV-Myc
mice. Groups of 30 uniparous MMTV-Myc female mice were given 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido]benzoic acid
(Am580) (0.3 mg/Kg/day) in the diet or control diet for up to 50 weeks. A) Time to palpable tumor development was recorded to determine
percent of mice with tumor-free survival over time. Kaplan-Meier analysis of the data indicated that numbers of mice with extended latency
were not significantly different between treated (Am580 (NR+R)) and untreated control (Myc-Ctrl) groups. However, separation of data from the
treated group at week 50 on the basis of positive response (Am580 R) or nonresponse (Am580 NR) to Am580 dosing, and reanalysis indicated
that the percent of Am580 R mice responding to Am580 as evidenced by the increased tumor latency, from the total Am580 (NR+R) group was
significantly higher than the percent of Myc-Ctrl mice (log-rank test, P = 0.0456). B) Tumor growth was recorded by measuring the two main
diameters weekly over an 8-week period beginning when tumors were palpable, and volumes were calculated as described in Methods. Analysis
of individual tumor growth per mouse indicated two distinct populations in the Am580 treatment group on the basis of tumor volume, namely
responders (Am580 R) and nonresponders (Am580 NR). C) Effect of Am580 on metastatic dissemination to lungs in the Myc-Ctrl, Am580 R and
Am580 NR experimental groups. The number of overt metastases per mouse lung was quantified under a Nikon stereoscope and plotted. The
statistical significance of the results was determined using the Mann-Whitney nonparametric test.
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Figure 7 Analysis of tumors from Am580-treated and untreated control mice. A) Immunoblotting analyses for E-cadherin, retinoic acid
receptor (RAR)a, RARg, phosphorylated Erk (activation) and p27 levels of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido]benzoic
acid (Am580)-responsive (Am580 R) and -nonresponsive (Am580 NR) tumors (three representatives from each group of five tumors shown).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. B) Immunohistochemical analyses of RARa-responsive
genes Cyp26A, E-cadherin and p27 (brown staining) in sections from (Am580 R, Am580 NR and Myc-Ctrl tumors; scale bar = 200 μm.
C) Immunohistochemical analysis for CRBP1 expression in tumor sections indicates that tumors from Am580 R mice expressed CRBP1, whereas
only stromal cells in tumor sections from the Am580 NR and Myc-Ctrl mice expressed CRBP1 (black arrows). Am580 R tumor sections had small
nodules of CRBP1-negative cells (white arrows); bar = 400 μm. D) H & E staining of a Myc-Ctrl tumor section reveals an invasive carcinoma with
very few necrotic areas, whereas a section from an Am580 NR tumor displays an increase in frequency of necrosis (white arrows; bar = 200 μm)
and that from an Am580 R tumor displays larger and more necrotic areas (white arrows; bar = 400 μm). Sections shown are representative of
five replicates. Immunohistochemical analysis was done on sections from eight tumors per experimental group.
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protein levels of RARa target genes by western blotting
and immunohistochemistry. As shown in Figure 7A,
tumor lysates of Am580-responsive mice treated with
Am580 exhibited increased levels of growth arrest (p27)
and differentiation (E-cadherin) markers compared to the
Am580-nonresponsive tumors. Tumor lysates of Am580treated nonresponsive mice also had increased levels of
p-Erk1/2 (Figure 7A), which also suggests an increased
proliferative response. RARa protein levels were low in
both Am580 treatment groups, whereas RARg was much
higher in the Am580 non-responsive tumors. Immunohistochemistry of tumor sections (Figure 7B) confirmed the
western blot results by showing enhanced levels of E-cadherin and p27 in the Am580 responsive tumors and also
revealed, that the RARa target gene involved in ATRA
catabolism, cytosolic Cyp26A1, was strongly induced in
these tumors compared to the Am580 nonresponsive and
Myc-Ctrl tumors. Both immunohistochemistry (Figure 7C)
and western blotting (Figure 8A) showed that Am580
treatment induced robust CRBP1 expression exclusively in
the responsive tumors. The only CRBP1-positive cells
detected in the untreated control and nonresponsive
tumors were host stromal cells (black arrows in Figure 7C
and data not shown). Interestingly, the responsive tumors
showed focal outgrowths negative for CRBP1 staining,
which may correspond to nonresponsive precursors (white
arrows in Figure 7C). Despite induction of several differentiation markers, no overt morphological signs of tissue differentiation, such as the acinar-like structures observed in
the three-dimensional cultures (Figure 1E), were detected
in these tumor sections. However, scattered necrotic areas
in both nonresponsive and responsive tumor sections were
observed and found to be bigger and more prevalent in
the responsive sections (Figure 7D, white arrows).
RARg down-regulates CRBP1 expression by direct
transcriptional repression

Since RARg and CRBP1 expression levels were inversely
regulated in c-Myc-expressing tumors (Figure 1B), as
shown by up-regulation of CRBP1 protein by RARg inhibition [39] and (Figure 1D), we explored the possibility that
ligand-free RARg could transcriptionally repress CRBP1.
We ectopically expressed RARg in primary mammary
epithelial cells isolated from FVB mice and analyzed its
effect on CRBP1 expression (mRNA) and protein levels
(Figure 8B and 8C, respectively) and found a slight downregulation in CRBP1 levels. ATRA treatment strongly
induced CRBP1 expression at mRNA (Figure 8B) and, to a
lesser degree, protein levels (Figure 8C). It is possible that
the CRBP1 protein level continues to accumulate beyond
the 24 h shown here, as was shown in rat Sertoli cells in
which the half-life of CRBP1 was calculated to be 48 h [62].
To test the regulation of CRBP1 in mammary epithelial
cells by retinoids, primary mammary epithelium from
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three 9-week-old FVB females, was treated for 3 days
with 100 nM Am580, 1 uM ATRA, 100 nM SR11253,
60 nM BMS961, or their combination and CRBP1 levels
were evaluated by western blot analysis (Figure 8D).
CRBP1 protein was increased by RARa agonist Am580
alone or with RARg agonist BMS961 (Figure 2 second
and eighth lanes) and by RAR pan-agonist ATRA plus
BMS961 (Figure 2 ninth lane) but reduced by RARg
antagonist SR11253. No major changes in CRBP1 expression level were observed in cells treated with ATRA,
Am580 plus SR11253, ATRA plus SR11253, or BMS961.
These results show that in contrast to Myc-expressing
cells, CRBP1 protein levels are reduced in normal mammary epithelium when RARg transcriptional activation is
blocked, suggesting that oncogenic stress changes the
RARg function, possibly through changes in the RARgassociated transcriptional complex, additional studies are
required to elucidate these differences.
Although we did not examine the composition of the
transcriptional complex, using ChiP assays we showed
that over-expression of RARg in normal mammary cells
led to an enrichment of RARg promoter (Figure 8E);
whereas treatment of these cells with ATRA led to a
slight CRBP1 reduction in CRBP1 promoter-associated
RARg and re-expression of CRBP1 (Figure 8B-D). These
results suggest a repressive role for RARg. Because ATRA
activates all three RAR isotypes, we propose that in normal cells, activated RARa competes with RARg for binding to the RARE in the CRBP1 promoter. Under the
influence of over-expressed c-Myc, the ratio of RARa/
RARg changes profoundly in favor of RARg, thus limiting
the ability of RARa to displace RARg from this promoter.

Discussion
Our data show that c-Myc over-expression in mammary
epithelial cells alters the RARa -b/RARg balance through
RARg up-regulation. The relative increase in RARg isotype
expression relative to the a and b isotypes correlates with
tumor progression and lack of expression of RARa target
genes involved in cell-cycle arrest and differentiation. In
contrast, a shift towards RARa activation by the selective
RARa agonist Am580 induces a tumor-inhibiting response
in MMTV-Myc mice. Of the Am580-treated mice,
approximately 63% responded to Am580 treatment by
showing an anti-tumor effect with decreased tumor
growth rates and lower incidence and number of lung
metastases, while the rest (37%) did not respond to
Am580. Only the responders displayed reduced levels of
RARg protein in their tumors, accompanied by increased
expression of RARa target genes.
Collectively, several specific results obtained here identify RARg as a pro-oncogenic RAR isotype. First, antagonism of RARg transactivation by pharmacologic levels of
its antagonist SR11253 dose-dependently halted the rapid
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Figure 8 CRBP1 is a downstream target of retinoic acid receptor (RAR)g. A) Immunoblotting analysis of CRBP1 protein in tumor lysates
from 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carboxamido]benzoic acid (Am580)-responsive (Am580 R) and Am580-nonresponsive
(Am580 NR) tumors. Results from three representative tumors from each experimental group are shown. Tubulin was used as a loading control.
B) and C) Quantitative (Q)-PCR analysis of CRBP1 gene expression in normal mammary epithelial cells obtained from FVB mice transfected with
RARg or vector control and treated with 1 uM All-trans retinoic acid (ATRA) or vehicle control for 48 h. D) Primary mammary epithelial cells
obtained from a normal FVB female mouse were isolated and used to generate a primary culture that was treated with each retinoid (100 nM
Am580, 1 uM ATRA, 100 nMSR11253 and 60 nM BMS961) for 72 h., CRBP1 protein levels were determined by western blot analysis. Results
shown are representative of three independent experiments. E) Chip analysis of lysates from normal FVB mammary epithelial cells treated or not
with 1 μM ATRA for 48 h to examine interaction of RARg with the CRBP1 gene promoter. Results presented are representative of three
independent experiments done in triplicate.
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growth of cells that over-expressed the oncogene Myc.
Second, RARg knockdown in MMTV-Myc cells, enabled
RARa-selective Am580 to more effectively inhibit cell
growth and to increase levels of the RARa target gene,
CRBP1. Moreover, CRBP1 expression was higher in
MMTV-Myc tumors in mice that responded to Am580
treatment. This result is important because we previously
reported that re-expression of CRBP1 was associated
with impaired tumor progression [42,43].
CRBP1 expression also decreased after normal mammary epithelial cells were ectopically transfected with
RARg, whereas specific pharmacologic activation of
RARg increased CRBP1 expression. The fact that in normal mammary epithelia RARg-mediated repression of
CRBP1 expression occurred only in the absence of its
agonist, or at low agonist concentration (due to the presence of retinol in the serum), suggests that additional
changes such as those induced by such oncogenes as
c-Myc are required to potentiate the gene repressive
function of RARg in the presence of ligand.
In addition to the role of RARg in Myc-mouse mammary epithelial cells, we documented its pro-oncogenic
role in human breast cancer cells lines. Knockdown of
RARg expression in immortalized epithelial MCF-10A
(ER-, non-tumorigenic), MCF-7 (ER+, tumorigenic) and
MDA-MB-231 (ER-, PR- and HER2-,tumorigenic) breast
cancer cell lines led to their reduced proliferation. With
the exception of MDA-MB-231 cells, proliferation was
further reduced by treatment with RARa agonist Am580.
The lack of response by MDA-MB-231 cells may most
likely be due to their low levels of RARa [59] (also see
Figure 3). This reduction in cellular proliferation by the
addition of Am580 implies that RARa is the tumor suppressor isotype. This conclusion was further strengthened
by the experiments (Figure 5) in which selective downregulation of RARa or RARb in MCF-10A cells promoted
the appearance of a less differentiated, more proliferative
phenotype, while reduction of RARg expression led to cellcycle arrest and reduced cell survival (Figure 5).
The results from the experiments using a genetic
approach to RAR isotype regulation were recapitulated
using synthetic RAR isotype-specific retinoids in both
human and the mouse cell lines. Individually, a RARa
agonist and a RARg antagonist reduced cell growth and
their combination was even more effective. The RARg
agonist significantly induced the growth of MCF7 breast
cancer cells. Interestingly, MDA-MB-231 cells, which did
not respond to Am580, became sensitized to Am580 by
co-treatment with RARg antagonist SR11253. The combination of Am580 with CD437/AHPN in the Myc cells
gave the strongest growth inhibition; we believe that this
strong response is probably related to the RAR-independent pro-apoptotic effects described for the CD437 that
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interestingly include the inhibition of c-Myc expression
[63-65]. In this regard Paroni et al. [66] have shown that
RARa was co-amplified in approximately one third of
ERBB2+ human breast cancers. In culture, treating such
cells with the ERBB2 inhibitor lapatinib combined with
ATRA synergistically inhibited growth, and induced cell
differentiation and apoptosis. We previously showed that
in transgenic mice bearing MMTV-Neu- and -Wnt1-driven tumors [39], and report here that in mice bearing
MMTV-Myc-driven tumors and in human breast cancer
cell lines, RARg expression is counterproductive to the
anti-cancer effects of ATRA. On this basis, we propose
that substituting a RARa-selective or specific agonist for
the RAR pan-agonist ATRA should improve the therapeutic response.
Our findings are unique in that they describe a specific
role for c-Myc-mediated differential regulation of RAR
isotypes in which predominance of RARg facilitates the
pro-oncogenic phenotype. Our results are in agreement
with the proliferative role of RARg in hematopoiesis [3]
and hepatocellular carcinoma [38]. We find that in the
context of c-Myc expression the oncogenic function of
RARg is potentiated. Myc increases RARg expression,
leading to changes in the stoichiometry between RAR
isotypes. Knockdown of RARg in MMTV-Myc-derived
cancer cells impaired tumor growth in a xenograft model
and induced markers of cell-cycle arrest, differentiation
and acinar-like morphogenesis in three-dimensional
cultures.
Functional specificity of RAR depends on the ability of
these isotypes to bind and recruit other co-repressors or
co-activators [67]. However, most studies to date have
focused on the presence of RARa or the lack of RARb.
Privalsky et al. showed that RARg has low affinity for classical co-repressors associated with nuclear receptors, such
as N-CoR or SMRT [68], suggesting a different mechanism of repression would be induced by RARg. In a recent
paper [69], RARg was shown to control both the association and dissociation of the chromatin repressor Suz12
from transcriptional complexes. Suz12 belongs to the
Polycomb Repressive Complex 2 and its up-regulation has
been associated with cancer and stem cell compartment
maintenance [70,71]. It is possible that oncogenic stress
induces an up-regulation of both RARg and Suz12, promoting an aberrant association between the two proteins
leading to abnormal RARg function and gene expression
outcome.
Polycomb Group (PcG) proteins are known to control
the recruitment of DNA methyltransferases (DNMT) to
target promoters [72] and it is possible that overexpressed RARg bound to the CRBP1 promoter favors
this process. This repressive effect of RARg on CRBP1
expression may be an early response to c-Myc oncogenic

Bosch et al. Breast Cancer Research 2012, 14:R121
http://breast-cancer-research.com/content/14/4/R121

transformation that reduces CRBP1 expression, which
later becomes permanent, by promoter hypermethylation
[73,74]. In such a scenario RARa may no longer be able
to compete for CRBP1 promoter occupancy so that cells
became insensitive to Am580 treatment. Although, this is
an attractive and testable scenario, we can exclude the
possibility that the decrease in CRBP1 expression caused
by RARg up-regulation is due to the lack of recruitment
of transcription activators to CRBP1 promoter, suggesting that RARg is a less efficient transactivator instead of
being a strict repressor. Further analysis is required to
determine how a shift in the RAR isotypes induced by cMyc affects co-activators, co-repressors and other regulatory components of the transcriptional complexes.
As a whole, our results suggest that RARg has an
opposite role in tumorigenesis than RARa or RARb.
Oncogenic stress, which deregulates important cell signaling pathways and alters the normal function of
nuclear receptors such as RARs, can induce RARg
expression and its pro-survival function inducing RARab/RARg imbalance and aberrant repression of RARatarget genes. Pharmacologic activation of RARa, or inhibition of RARg activity, reduces cancer cell growth in
vitro, thereby suggesting that a specific RARa agonist
would be a more effective method of cancer treatment
than an RAR pan-agonist such us ATRA.

Conclusions
Genetic and pharmacologic approaches in cell culture
and in vivo allowed us to conclude that maintenance of
a proper RARab/g balance is crucial for preserving normal epithelial cell homeostasis. An oncogenic signal
initiated by c-Myc over-expression increases RARg
expression, which perturbs the RARab/g balance in
favor of RARg. The consequence of this change is
down-regulation of tumor suppressive genes such as
RARa, RARb and CRBP1, and possibly others. This protumorigenic c-Myc induced effect can be overcome by
selective activation of RARa that leads to the re-expression of CRBP1 and reversion of the malignant phenotype. Elucidating the mechanism through which RAR
isotypes are involved in c-Myc tumorigenesis is clinically relevant since c-Myc expression is altered in 25%
of human breast cancers [75-78]. The combined results
of the present study alongside those previously published [39] support the use of a RARa-selective agonist
and/or RARg-selective antagonist as a therapeutic
approach for a subset of patients. We propose that
determining the balance of RAR isotypes in cancer tissues compared to normal ones will improve tumor classification and will identify those tumors in which RAR
isotype-selective intervention would be of benefit to the
patients.
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Additional material
Additional file 1: Figure S1: Gene expression controls. A) Quantitative
(Q)-PCR showing expression levels of human c-Myc in FVB mammary
epithelial cells after transfection with pcDNA3 vector control (FVB-Ctrl) or
with pcDNA3-h-c-Myc (FVB-Myc). B) Q-PCR showing retinoic acid
receptor (RAR) g expression is knocked-down by shRARg in Myc cells.
Additional file 2: Figure S2: Am580 NR and Am580 R xenograft
responses to Am580. Because the mouse mammary tumor virus
(MMTV) promoter can be expressed in some cells of the immune system,
it was important to determine whether the MMTV-Myc xenograft host
FVB animal influenced response to 4-[(5,6,7,8-tetrahydro-5,5,8,8tetramethyl-2-naphthyl)carboxamido]benzoic acid (Am580) treatment.
Therefore, tumor cells obtained from two Am580-nonresponsive (NR1
and NR2) and two Am580-responsive (R1 and R2) xenografts that had
been obtained from Am580-treated MMTV-Myc mice were injected into
the abdominal mammary fat pad of FVB syngenic females (n = 10,
analysis of variance P<0.001) and tumor growth was monitored. Both
Am580 R and Am580 NR xenografts retained their respective slow and
fast tumor growth rates in their FVB hosts as those observed in tumors
from the original transgenic groups indicating that growth behavior was
intrinsic to the tumors, and not associated with an immunologic
response by the host mice.

Abbreviations
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